骨髓库姆试验（+）血细胞减少患者骨髓造血细胞自身抗体IgG破坏或抑制造血的机制研究
|
摘要
目的
初步探讨骨髓单个核细胞库姆(BMMNC-Coombs)试验(+)血细胞减少(又称免疫相关性全血细胞减少，immunorelated pancytopenia，IRP)患者骨髓造血细胞自身抗体IgG破坏和／或抑制造血机制。
方法
选取IRP患者为研究对象，以重型再生障碍性贫血(SAA)及正常人分别为病例及正常对照，进行下述研究：第一部分IRP患者骨髓红系造血岛(EI)形成机制。(1)采用流式细胞术(FACS)检测IRP患者骨髓细胞(CD34+、CD15+及GlycoA+细胞)膜抗体(IgG、IgM)类型；(2)采用免疫荧光(IF)法标记48例IgG(+)的IRP患者骨髓EI，观察自身抗体IgG在EI分布；(3)探讨EI自身抗体分布与IRP患者病情相关性。第二部分骨髓巨噬细胞(M_Φ)数量、活化抗原表达及功能研究。(1)采用流式细胞术(FACS)检测IRP患者骨髓细胞(CD34+、CD15+及GlycoA+细胞)膜抗体(IgG、IgM)类型；(2)采用FACS检测61例IgG(+)IRP患者骨髓M_Φ数量[(CD68+／CD45+)％]、活化抗原(CD69)表达水平[(CD68+CD69+／CD68+)％]；(3)采用鸡红细胞(CRBC)吞噬试验评价骨髓M_Φ吞噬率和吞噬指数。第三部分骨髓造血细胞膜功能受体封闭研究。FACS检测骨髓GlycoA(+)细胞膜EPO受体(EPOR)和自身抗体IgG；在含不同浓度EPO的培养基中培养骨髓干祖细胞，7天检测红系集落(CFU-E)产率。
结果
第一部分(1)48例IRP患者中有14例(29．17％)骨髓“EI”的IF阳性，即EI中巨噬细胞和幼红细胞间沉积自身抗体IgG。(2)这14例患者骨髓GlycoA(+)细胞膜上均(100％)测及自身抗体IgG，贫血是首发症状，以重度贫血为主[重度贫血9例(64．29％)，中度贫血5例(35．71％)]；余34例未测及EI中有自身抗体IgG沉积者仅2例(5．89％)，其贫血程度轻。(3)14例EI有自身抗体IgG沉积患者的网织红细胞比例[(2．0±0．8)％]、胸骨红系比例[(44．1±13．9)％]及间接胆红素水平[(9．4±4．7)mmol／1]均明显高于EI中无IgG沉积者[(1．3±1．0)％，(29．8±8．2)％，(6．6±6．7)mmol／l](P＜0．05)，而前者的血红蛋白水平[(59．6±16．2)g／l]低于后者[(83．4±25．0)g／l](P＜0．05)。(4)EI有自身抗体IgG沉积患者3、6个月总有效率(57．14％、85．71％)优于EI无自身抗体IgG沉积患者(P＜0．05)(32．26％、61．29％)。第二部分61例IRP患者骨髓M_Φ数量、活化抗原表达、CRBC吞噬率及吞噬指数[(0．57±0．30)％，(40．30±18．49)％，(37．56±15．20)％和(0．75±0．34)]均高于10例SAA患者[(0．46±0．08)％，(32．44±19．37)％，(28．26±10．46)％和(0．59±0．39)]及13名正常人[(0．44±0．69)％，(29．71±11．67)％，(25．63±14．75)％和(0．55±0．16)](P＜0．05)；且M_Φ数量与活化抗原表达、吞噬率及吞噬指数均呈正相关(r=0．89，p＜0．01；r=0．43，p＜0．01；r=0．40，p＜0．01)。根据M_Φ数量将IRP患者分为A组(M_Φ≥0．5％)和B组(M_Φ＜0．5％)，A组34例患者中32例(94．12％)自身抗体为IgG，B组27例患者中仅2例(7．41％)自身抗体为IgG；A组患者M_Φ的活化抗原表达、CRBC吞噬率及吞噬指数[(49．19±16．63)％，(46．62±13．38)％，(0．91±0．36)]显著高于B组患者[(29．11±14．30)％，(28．67±12．59)％，(0．61±0．30)](P＜0．05)，而B组患者与SAA及正常人无显著性差异(P＞0．05)。将34例BMMNC-IgG(+)型患者分为M_Φ高(≥0．75％)、低水平(＜0．75％)2组，25例(73．53％)M_Φ低水平患者均仅能检测到一系骨髓细胞(CD34+／或CD15+／或GlycoA+)有IgG，9例(23．53％)M_Φ高水平患者有8例能检测到二系骨髓细胞有IgG，1例(2．94％)是三系骨髓细胞均有IgG；M_Φ高水平的IRP患者M_Φ的活化抗原表达、CRBC吞噬率及吞噬指数[(56．12±15．11)％，(60．22±12．51)％，(1．23±0．23)]显著高于M_Φ低水平患者[(44．58±18．16)％，(43．32±9．24)％，(0．84±0．24)](P＜0．05)。M_Φ高水平患者外周血红细胞计数、血红蛋白水平、血小板计数均显著低于M_Φ低水平患者(P＜0．05)；M_Φ高水平患者的网织红细胞比例、胆红素水平及胸骨红系比例均显著高于M_Φ低水平患者(P＜0．05)。第三部分(1)24例骨髓GlycoA(+)细胞膜IgG(+)的IRP患者骨髓GlycoA(+)细胞膜EPOR水平[(4．16±0．15)％]显著低于10名正常人[(6．04±0．48)％](P＜0．05)。(2)这些IRP患者骨髓细胞体外培养，CFU-E产率与EPO浓度的关系呈两种形式：EPOR低水平组1的拟合方程为：y=1．0028x-2．0056，(P＜0．05，g＜0．05)，回归检验有显著性，失拟检验回归方程拟合良好，呈线性关系，提示有增长趋势；EPOR低水平组2数据行拟和检验结果：F=0．25，P=0．6264，g=0．16，为非线性关系，无增长变化趋势；正常人拟合方程为：y=0．68915x-1．9783(P＜0．05，g＜0．05)，回归检验有显著性，失拟检验回归方程拟合良好，呈线性关系，提示有增长趋势。
结论
IRP患者自身抗体IgG抑制和／或破坏骨髓造血的机制可能是：
(1)激活M_Φ吞噬和破坏带有自身抗体IgG的骨髓造血细胞导致骨髓造血功能衰竭；
(2)部分自身抗体IgG通过与骨髓造血细胞膜功能抗原(如EPOR)结合，使骨髓造血细胞缺乏必需造血生长因子刺激从而影响其增殖和分化。
OBJECTIONS
To explore the pathogenetic mechanism of destruction and/or supp-ression of hematopoiesis by auto-antibodies(IgG)on bone marrow cellsin pancytopenia patients with positive BMMNC-Coombs Test(immunorelatedpancytopenia,IRP).
METHODS
IRP cases,severe aplastic anemia (SAA)and normal controls wereenrolled in this study.The categories of auto-antibodies(IgG、IgM)onBMMNC (CD34+/CD15+/GlycoA+ hematocytes)were assayed by fluorescenceactivated cell sorting (FACS).First Section The auto antibodies(IgG)in the“EI”on the BM smears of forty-eight cases with IRP、ten SAA andeleven normal controls were detected by immuno-histofluorescence (IF)staining.Clinical and laboratory data of all cases and controls werealso analyzed respectively.Second Section Sixty-one cases with IRP,tenSAA and thirteen normal controls were enrolled in this study.The quantity(the percent of CD68+/CD45+)and the expression of activated antigens (thepercent of CD69+CD68+/CD68+)of macrophages in the bone marrow of allcases and controls were measured by FACS and the function of macrophageswere evaluated according to the phagocytosis ratio and index of red bloodcells(CRBC)phagocytosed by macrophages which was cultured in vitro.Third Section EPO receptors(EPOR)on GlycoA(+)BMMNCs of IRP patientswith IgG(+)on GlycoA(+)BMMNCs were measured by FACS.The hemopoieticprecursors of BM were cultured in different levels of erythropoietin (EPO)in vitro and colony-forming units-erythoid (CFU-E)were observed at7-day-culture.
RESULTS
First Section (1)Mouse anti-human IgG could be detected on the BMsmear of 14 cases(29.17%),which deposited on the junction betweenmacrophagesanderythroblasts in the“EI”s,IgGon theGlycoA(+)cellsthese 14 cases were all founded.The initial clinical feature of the 14cases with auto antibodies(IgG)in the EI was anemia〔severe anemia (64.29%),middle degree anemia (35.71%)〕,concentration of hemoglobin〔(59.6±16.2)g/l〕in peripheral blood of cases with auto antibodies(IgG)inthe EI were lower than those〔(83.4±25.0)g/l〕of 34 cases without autoantibodies(IgG)in the EI (P＜0.05),but the percent ofreticulocyte(Ret)count〔(2.0±0.8)%〕、the ration of erythroid in the bone marrow fromsternum〔(44.1±13.9)%〕and the level of IBIL of the formers〔(9.4±4.7)mmol/l)higher (P＜0.05)(P＜0.05);Cases with auto antibodies (IgG)in the EI had good reponse to high doses of IVIG (HDIVIG)or /andGlucocorticoids therapies.Total curative rate at 3 and 6 month(indivi-dually 57.14%、85.71%)of cases with auto antibodies(IgG)in the EIwere better than those of the cases without auto antibodies(IgG)in theEI (P＜0.05)respectively.Second Section the quantity,expression ratioof activatedantigen,phagocytosisratioandindex〔(0.57±0.30)%,(40.30±18.49)%,(37.56±15.20)%和(0.75±0.34)〕of BM macrophages in IRPpatients were respectively significantly higher than those in all thecontrol cases〔(0.46±0.08)%,(32.44±19.37)%,(28.26±10.46)%和(0.59±0.39)〕(P＜0.05).And the quantity present high-positive correlationwith the expression ratio of activated antigen phagocytosis ratio andindex of BM macrophages (r=0.89,p＜0.01;r=0.43,p＜0.01;r=0.40,p＜0.01).Patients with IRP were classified into two subgroups according to the quantity of macrophages:Group A(M_Φ≥0.5%)(34casese)and Group B(M_Φ＜0.5%)(27cases),32 cases (94.12%)with auto antibodies(IgG)in Group A,only 2 cases(7.41%)with auto antibodies(IgG)in Group B.There weresignificant differences in expression ratio of activated antigen,phagocytosis ratio and index of macrophages between Group A〔(49.19±16.63)%,(46.62±13.38)%,(0.91±0.36)〕andGroupB〔(29.11±14.30)%,(28.67±12.59)%,(0.61±0.30)〕(P＜0.05).Thirty-four cases of IRP wasdivided into two subgroups according to the quantity of M_Φ:high levelgroup(≥0.75%)(25cases)and Low level group (＜0.75%)(9cases),24 casesin M_Φhigh level group with auto antibodies(IgG)on one hemotopoietic celllineage,l on two lineages,while 8 cases in M_ΦLow level group with autoantibodies(IgG)on two cell lineages,and l on three cell lineages.Theexpression ratio of activated antigen,phagocytosis ration and index ofmacrophages were much higher in high level group〔(56.12±15.11)%,(60.22±12.51)%,(1.23±0.23)〕than those〔(44.58±18.16)%,(43.32±9.24)%,(0.84±0.24)〕in low level group(P＜0.05).The count of RBC、concentration of HbandBPCin peripheral blood of high level group wererespectively lower than those in low level group(P＜0.05).While thepercentage of Ret,the level of TBIL and the ratio of erythroid of sternalbone marrow in high level group were higher than those in low levelgroup(P＜0.05).Third Section The level of EPO receptors(EPOR)onGlycoA(+)BMMNCs of IRP patients with IgG(+)on GlycoA(+)BMMNCs〔(4.16±0.15)%〕was lower than that of normal controls〔(6.04±0.48)%〕(P＜0.05).There were two different relationships between CFU-E and EPO level.Therewere twenty patients in Group 1 and four cases in Group2.The equationtest of goodness of fit in Grouplwasy=l.OO28x-2.0056,(P＜0.05,g＜0.05). There was no linearity correlation between CFU-E and EPO level (F=0.25,P=0.6264,g=0.16)in Group2.The equation test of goodness of fit in normalcontrol was y=0.68915x-1.9783 (P＜0.05,g＜0.05).
CONCLUSION
(1)Macrophage connected with erythroblasts by auto antibodies(IgG)in the“EI”s of some of IRP patients.These“EI”s were not niches oferythroblastic developmentment and differenttiation but where macroph-ages devoured and destroyed erythroblasts in vivo.Macrophages didn't nurse but devour erythroblasts.The pathogentic mechanism of IRP withauto antibodies(IgG)in the EI may be that macrophages devoured morehematopoietic cells.(2)The quantity、expression ratio of activatedangtigen and phagocytosis ratio and index of macrophages were enhancedin IRP patients with auto antibodies(IgG).When the numbers of hematopoi-eric cells with auto antibodies(IgG)of bone marrow phogocytosed bymacrophages which were activated were more than those of the hematopo-ietic cells which are produced by bone morrow,bone marrow failure canoccur.Macrophages might not involved in destruction of bone marrow inIRP with auto antibodies(IgM)or cold autoantibodies.(3)Maybe autoantibodies (IgG)which combinated with EPOR on hematopoietic cells blockEPO-EPOR signation and hematopoietic cells could not proliferate anddifferentiate,then the absence of EPO causes bone marrow failure.
初步探讨骨髓单个核细胞库姆(BMMNC-Coombs)试验(+)血细胞减少(又称免疫相关性全血细胞减少，immunorelated pancytopenia，IRP)患者骨髓造血细胞自身抗体IgG破坏和／或抑制造血机制。
方法
选取IRP患者为研究对象，以重型再生障碍性贫血(SAA)及正常人分别为病例及正常对照，进行下述研究：第一部分IRP患者骨髓红系造血岛(EI)形成机制。(1)采用流式细胞术(FACS)检测IRP患者骨髓细胞(CD34+、CD15+及GlycoA+细胞)膜抗体(IgG、IgM)类型；(2)采用免疫荧光(IF)法标记48例IgG(+)的IRP患者骨髓EI，观察自身抗体IgG在EI分布；(3)探讨EI自身抗体分布与IRP患者病情相关性。第二部分骨髓巨噬细胞(M_Φ)数量、活化抗原表达及功能研究。(1)采用流式细胞术(FACS)检测IRP患者骨髓细胞(CD34+、CD15+及GlycoA+细胞)膜抗体(IgG、IgM)类型；(2)采用FACS检测61例IgG(+)IRP患者骨髓M_Φ数量[(CD68+／CD45+)％]、活化抗原(CD69)表达水平[(CD68+CD69+／CD68+)％]；(3)采用鸡红细胞(CRBC)吞噬试验评价骨髓M_Φ吞噬率和吞噬指数。第三部分骨髓造血细胞膜功能受体封闭研究。FACS检测骨髓GlycoA(+)细胞膜EPO受体(EPOR)和自身抗体IgG；在含不同浓度EPO的培养基中培养骨髓干祖细胞，7天检测红系集落(CFU-E)产率。
结果
第一部分(1)48例IRP患者中有14例(29．17％)骨髓“EI”的IF阳性，即EI中巨噬细胞和幼红细胞间沉积自身抗体IgG。(2)这14例患者骨髓GlycoA(+)细胞膜上均(100％)测及自身抗体IgG，贫血是首发症状，以重度贫血为主[重度贫血9例(64．29％)，中度贫血5例(35．71％)]；余34例未测及EI中有自身抗体IgG沉积者仅2例(5．89％)，其贫血程度轻。(3)14例EI有自身抗体IgG沉积患者的网织红细胞比例[(2．0±0．8)％]、胸骨红系比例[(44．1±13．9)％]及间接胆红素水平[(9．4±4．7)mmol／1]均明显高于EI中无IgG沉积者[(1．3±1．0)％，(29．8±8．2)％，(6．6±6．7)mmol／l](P＜0．05)，而前者的血红蛋白水平[(59．6±16．2)g／l]低于后者[(83．4±25．0)g／l](P＜0．05)。(4)EI有自身抗体IgG沉积患者3、6个月总有效率(57．14％、85．71％)优于EI无自身抗体IgG沉积患者(P＜0．05)(32．26％、61．29％)。第二部分61例IRP患者骨髓M_Φ数量、活化抗原表达、CRBC吞噬率及吞噬指数[(0．57±0．30)％，(40．30±18．49)％，(37．56±15．20)％和(0．75±0．34)]均高于10例SAA患者[(0．46±0．08)％，(32．44±19．37)％，(28．26±10．46)％和(0．59±0．39)]及13名正常人[(0．44±0．69)％，(29．71±11．67)％，(25．63±14．75)％和(0．55±0．16)](P＜0．05)；且M_Φ数量与活化抗原表达、吞噬率及吞噬指数均呈正相关(r=0．89，p＜0．01；r=0．43，p＜0．01；r=0．40，p＜0．01)。根据M_Φ数量将IRP患者分为A组(M_Φ≥0．5％)和B组(M_Φ＜0．5％)，A组34例患者中32例(94．12％)自身抗体为IgG，B组27例患者中仅2例(7．41％)自身抗体为IgG；A组患者M_Φ的活化抗原表达、CRBC吞噬率及吞噬指数[(49．19±16．63)％，(46．62±13．38)％，(0．91±0．36)]显著高于B组患者[(29．11±14．30)％，(28．67±12．59)％，(0．61±0．30)](P＜0．05)，而B组患者与SAA及正常人无显著性差异(P＞0．05)。将34例BMMNC-IgG(+)型患者分为M_Φ高(≥0．75％)、低水平(＜0．75％)2组，25例(73．53％)M_Φ低水平患者均仅能检测到一系骨髓细胞(CD34+／或CD15+／或GlycoA+)有IgG，9例(23．53％)M_Φ高水平患者有8例能检测到二系骨髓细胞有IgG，1例(2．94％)是三系骨髓细胞均有IgG；M_Φ高水平的IRP患者M_Φ的活化抗原表达、CRBC吞噬率及吞噬指数[(56．12±15．11)％，(60．22±12．51)％，(1．23±0．23)]显著高于M_Φ低水平患者[(44．58±18．16)％，(43．32±9．24)％，(0．84±0．24)](P＜0．05)。M_Φ高水平患者外周血红细胞计数、血红蛋白水平、血小板计数均显著低于M_Φ低水平患者(P＜0．05)；M_Φ高水平患者的网织红细胞比例、胆红素水平及胸骨红系比例均显著高于M_Φ低水平患者(P＜0．05)。第三部分(1)24例骨髓GlycoA(+)细胞膜IgG(+)的IRP患者骨髓GlycoA(+)细胞膜EPOR水平[(4．16±0．15)％]显著低于10名正常人[(6．04±0．48)％](P＜0．05)。(2)这些IRP患者骨髓细胞体外培养，CFU-E产率与EPO浓度的关系呈两种形式：EPOR低水平组1的拟合方程为：y=1．0028x-2．0056，(P＜0．05，g＜0．05)，回归检验有显著性，失拟检验回归方程拟合良好，呈线性关系，提示有增长趋势；EPOR低水平组2数据行拟和检验结果：F=0．25，P=0．6264，g=0．16，为非线性关系，无增长变化趋势；正常人拟合方程为：y=0．68915x-1．9783(P＜0．05，g＜0．05)，回归检验有显著性，失拟检验回归方程拟合良好，呈线性关系，提示有增长趋势。
结论
IRP患者自身抗体IgG抑制和／或破坏骨髓造血的机制可能是：
(1)激活M_Φ吞噬和破坏带有自身抗体IgG的骨髓造血细胞导致骨髓造血功能衰竭；
(2)部分自身抗体IgG通过与骨髓造血细胞膜功能抗原(如EPOR)结合，使骨髓造血细胞缺乏必需造血生长因子刺激从而影响其增殖和分化。
OBJECTIONS
To explore the pathogenetic mechanism of destruction and/or supp-ression of hematopoiesis by auto-antibodies(IgG)on bone marrow cellsin pancytopenia patients with positive BMMNC-Coombs Test(immunorelatedpancytopenia,IRP).
METHODS
IRP cases,severe aplastic anemia (SAA)and normal controls wereenrolled in this study.The categories of auto-antibodies(IgG、IgM)onBMMNC (CD34+/CD15+/GlycoA+ hematocytes)were assayed by fluorescenceactivated cell sorting (FACS).First Section The auto antibodies(IgG)in the“EI”on the BM smears of forty-eight cases with IRP、ten SAA andeleven normal controls were detected by immuno-histofluorescence (IF)staining.Clinical and laboratory data of all cases and controls werealso analyzed respectively.Second Section Sixty-one cases with IRP,tenSAA and thirteen normal controls were enrolled in this study.The quantity(the percent of CD68+/CD45+)and the expression of activated antigens (thepercent of CD69+CD68+/CD68+)of macrophages in the bone marrow of allcases and controls were measured by FACS and the function of macrophageswere evaluated according to the phagocytosis ratio and index of red bloodcells(CRBC)phagocytosed by macrophages which was cultured in vitro.Third Section EPO receptors(EPOR)on GlycoA(+)BMMNCs of IRP patientswith IgG(+)on GlycoA(+)BMMNCs were measured by FACS.The hemopoieticprecursors of BM were cultured in different levels of erythropoietin (EPO)in vitro and colony-forming units-erythoid (CFU-E)were observed at7-day-culture.
RESULTS
First Section (1)Mouse anti-human IgG could be detected on the BMsmear of 14 cases(29.17%),which deposited on the junction betweenmacrophagesanderythroblasts in the“EI”s,IgGon theGlycoA(+)cellsthese 14 cases were all founded.The initial clinical feature of the 14cases with auto antibodies(IgG)in the EI was anemia〔severe anemia (64.29%),middle degree anemia (35.71%)〕,concentration of hemoglobin〔(59.6±16.2)g/l〕in peripheral blood of cases with auto antibodies(IgG)inthe EI were lower than those〔(83.4±25.0)g/l〕of 34 cases without autoantibodies(IgG)in the EI (P＜0.05),but the percent ofreticulocyte(Ret)count〔(2.0±0.8)%〕、the ration of erythroid in the bone marrow fromsternum〔(44.1±13.9)%〕and the level of IBIL of the formers〔(9.4±4.7)mmol/l)higher (P＜0.05)(P＜0.05);Cases with auto antibodies (IgG)in the EI had good reponse to high doses of IVIG (HDIVIG)or /andGlucocorticoids therapies.Total curative rate at 3 and 6 month(indivi-dually 57.14%、85.71%)of cases with auto antibodies(IgG)in the EIwere better than those of the cases without auto antibodies(IgG)in theEI (P＜0.05)respectively.Second Section the quantity,expression ratioof activatedantigen,phagocytosisratioandindex〔(0.57±0.30)%,(40.30±18.49)%,(37.56±15.20)%和(0.75±0.34)〕of BM macrophages in IRPpatients were respectively significantly higher than those in all thecontrol cases〔(0.46±0.08)%,(32.44±19.37)%,(28.26±10.46)%和(0.59±0.39)〕(P＜0.05).And the quantity present high-positive correlationwith the expression ratio of activated antigen phagocytosis ratio andindex of BM macrophages (r=0.89,p＜0.01;r=0.43,p＜0.01;r=0.40,p＜0.01).Patients with IRP were classified into two subgroups according to the quantity of macrophages:Group A(M_Φ≥0.5%)(34casese)and Group B(M_Φ＜0.5%)(27cases),32 cases (94.12%)with auto antibodies(IgG)in Group A,only 2 cases(7.41%)with auto antibodies(IgG)in Group B.There weresignificant differences in expression ratio of activated antigen,phagocytosis ratio and index of macrophages between Group A〔(49.19±16.63)%,(46.62±13.38)%,(0.91±0.36)〕andGroupB〔(29.11±14.30)%,(28.67±12.59)%,(0.61±0.30)〕(P＜0.05).Thirty-four cases of IRP wasdivided into two subgroups according to the quantity of M_Φ:high levelgroup(≥0.75%)(25cases)and Low level group (＜0.75%)(9cases),24 casesin M_Φhigh level group with auto antibodies(IgG)on one hemotopoietic celllineage,l on two lineages,while 8 cases in M_ΦLow level group with autoantibodies(IgG)on two cell lineages,and l on three cell lineages.Theexpression ratio of activated antigen,phagocytosis ration and index ofmacrophages were much higher in high level group〔(56.12±15.11)%,(60.22±12.51)%,(1.23±0.23)〕than those〔(44.58±18.16)%,(43.32±9.24)%,(0.84±0.24)〕in low level group(P＜0.05).The count of RBC、concentration of HbandBPCin peripheral blood of high level group wererespectively lower than those in low level group(P＜0.05).While thepercentage of Ret,the level of TBIL and the ratio of erythroid of sternalbone marrow in high level group were higher than those in low levelgroup(P＜0.05).Third Section The level of EPO receptors(EPOR)onGlycoA(+)BMMNCs of IRP patients with IgG(+)on GlycoA(+)BMMNCs〔(4.16±0.15)%〕was lower than that of normal controls〔(6.04±0.48)%〕(P＜0.05).There were two different relationships between CFU-E and EPO level.Therewere twenty patients in Group 1 and four cases in Group2.The equationtest of goodness of fit in Grouplwasy=l.OO28x-2.0056,(P＜0.05,g＜0.05). There was no linearity correlation between CFU-E and EPO level (F=0.25,P=0.6264,g=0.16)in Group2.The equation test of goodness of fit in normalcontrol was y=0.68915x-1.9783 (P＜0.05,g＜0.05).
CONCLUSION
(1)Macrophage connected with erythroblasts by auto antibodies(IgG)in the“EI”s of some of IRP patients.These“EI”s were not niches oferythroblastic developmentment and differenttiation but where macroph-ages devoured and destroyed erythroblasts in vivo.Macrophages didn't nurse but devour erythroblasts.The pathogentic mechanism of IRP withauto antibodies(IgG)in the EI may be that macrophages devoured morehematopoietic cells.(2)The quantity、expression ratio of activatedangtigen and phagocytosis ratio and index of macrophages were enhancedin IRP patients with auto antibodies(IgG).When the numbers of hematopoi-eric cells with auto antibodies(IgG)of bone marrow phogocytosed bymacrophages which were activated were more than those of the hematopo-ietic cells which are produced by bone morrow,bone marrow failure canoccur.Macrophages might not involved in destruction of bone marrow inIRP with auto antibodies(IgM)or cold autoantibodies.(3)Maybe autoantibodies (IgG)which combinated with EPOR on hematopoietic cells blockEPO-EPOR signation and hematopoietic cells could not proliferate anddifferentiate,then the absence of EPO causes bone marrow failure.
引文
[1]Valent P,Horny HP,Bennett JM,et al.Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes:Consensus statements and report from a working conference.Leuk Res.2007 31(6):727-736.
[2]Wimazal F,Fonatsch C,Thalhammer R,et al .Idiopathic cytopenia of undetermined significance(ICUS)versus low risk MDS:the diagnostic interface.Leuk Res.2007,31(11):1461-1468.
[3]和虹，邵宗鸿，刘鸿等．与异常免疫相关的全血细胞减少症．中华血液学杂志，2001，22：79-82．
[4]Hong He,Zonghong Shao,Rong Fu,et al.Hemocytopenia related to immunity detected by modified Coombs test for measuring autoantibody of bone marrow mononuclear cells.BLOOD,2002,100:136b.
[5]张之南，沈悌，主编。血液病诊断及疗效标准．第三版，北京：科学技术出版社，2007．
[6]和虹，邵宗鸿，曹增等．骨髓单个核细胞抗人球蛋白分型实验．中华血液学杂志，2000，21：550-551．
[7]和虹，邵宗鸿．改良直接抗人球蛋白试验的进展．中华检验医学杂志，2001，24(5)：313-315．
[8]RongFu,ZonghongShao,HongLiu,etal.Type,Distribution,andClinical Significance of Auto-antibody on Bone Marrow Hematopoietic Cells in Patients with Immuno-Related Pancytopenia.BLOOD,2002,100:136b.
[9]J acqueline H,Audrey L,Joel A,et al.Regulation of differentiation of Peritoneal B-la(CD5+)B cell.J Immunol,1995,154:5630-5636.
[10]Loza E,Tintue T,Sanchez-Ibarrola A.CD5 and CD23 expression on B cells in peripheral blood and synovial fluid of rheumatoid arthritis patients:relationship with interleukin-4、soluble CD23 and tumor necrosis factor alpha levels.Rheumatology,1999,38:325-328.
[11]Xing LM,Shao ZH,Fu R,et al.Subtypes of B lymphocytes in patients with autoimmune hemocytopenia.Chin Med Sci J.2007,22(2):128-131.
[12]付蓉，邵宗鸿，和虹等．免疫相关性全血减少症患者骨髓B淋巴细胞数量及凋亡相关蛋白水平．中华血液学杂志，2002，23：236-238．
[13]Rong Fu,Zonghong Shao,Hong he,et al.The quantities and apoptosis -related protein levels of B lymphocytes in patients with immunorelated pancytopenia.BLOOD,2002,100:171b.
[14]Fu R,Shao ZH,Liu H,et al.Role of B lymphocyte and its subpopulations in pathogenesis of immunorelated pancytopenia.Chin Med Sci J.2007,22(3):199-202.
[15]Siszar A,Nagy GY,Gergely P,et al.Increased IFN-γ,IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cell(PBMC)from patients with SLE.Clin Exp Immunol,2002,122:464-470.
[16]付蓉，邵宗鸿，刘鸿等．与免疫相关的血细胞减少患者骨髓造血祖细胞增殖功能测定及T辅助淋巴细胞功能观察．中华血液学杂志，2004，25：213-216．
[17]邵宗鸿，付蓉．免疫相关性血细胞减少症一种新认知的疾病(上)．中国医刊，2005，40：5-8．
[18]邵宗鸿，付蓉．免疫相关性血细胞减少症一种新认知的疾病(下)．中国医刊，2005，41：6-9．
[19]Julius U,Patzak A,Schaich M,Ehninger G,Kamin G Immune thrombocyto -penia,anemia and leukopenia during pregnancy.Successful therapy with extracorporeal immunoadsorption Dtsch Med Wochenschr. 1997, 122(8): 220-224.
[20] Favara BE,Jaffe R, Egeler RM.Macrophage activation and hemophago—cytic syndrome in langerhans cell histiocytosis:report of 30 cases. Pediatr Dev Pathol. 2002, 5(2):130-140.
[21] Lonceint J, Sassolas B, Lefur JM, Guillet G, Leroy JP. Panniculitis and macrophage activation syndrome in a child with lupus erythematosus.Ann Dermatol Venereol.2001, 128(12):1339-1342.
[22] Kelaidi C, Buturuga A, Dousset B, Calmus Y, Dreyfus F, Bouscary D.Autoimmune pancytopenia as an early complication of liver transplantation:report of one case. Leuk Lymphoma.2004,45(9):1951-1953.
[23] Deji N, Sugimoto T, Fujimoto T, Aoyama M, Takeda N, Sakaguchi M, Uzu T,Kashiwagi A. Emergence of panniculitis and haemophagocytic syndrome in a patient with chronic systemic lupus erythematosus. Lupus.2007, 16(5): 363-3655.
[24] Coutelier JP, Detalle L, Musaji A, et al.Two-step mechanism of virus-induced autoimmune hemolytic anemia. Ann N Y Acad Sci,2007,1109:151-157.
[25] Tesch GH. MCP-1/CCL2:a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.Am J Physiol Renal Physiol, 2008,13 [Epub ahead of print].
[26] Ghee J Y, Han D H, Song H K, et al.The role of macrophage in the pathogenesis of chronic cyclosporine nephropathy. Nephrol.Dial.Transplant, 2008, 23:4061-4069.
[27] Voskoboynik A, Rinkevich B, Weiss A, et al. Macrophage involvement for successful degeneration of apoptotic organs in the colonial urochordate Botryllus schlosseri. J. Exp.Biol, 2004, 207:2409-2416.
[28] Jo S K, Sung S A, Cho W Y, et al. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol.Dial. Transplant,2006,21:1231-1239.
[29] Kunisch E, Fuhrmann R,Roth A, et al. Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. Ann Rheum Dis, 2004, 63:774-784.
[30] Sawhney S, Woo P, Murray K J. Macrophage activation syndrome:a potentially fatal complication of rheumatic isorders.Arch.Dis.Child, 2001,85:421-426.
[31] Mevorach D, Mascarenhas J O, Gershov D, et al. Complement-dependent Clearance of Apoptotic Cells by Human Macrophages. J. Exp. Med, 1998,188:2313.
[32] Thomas E.Hamilton, Scott D,Lynn O,et al. Thyrotropin Levels in a Population with No Clinical, Autoantibody, or Ultrasonographic Evidence of Thyroid Disease:Implications for the Diagnosis of Subclinical Hypothyroidism. J. Clin. Endocrinol. Metab,2008,93:1224-1230.
[33] Agate L, Mariotti S, Elisei R, et al.Thyroid Autoantibodies and Thyroid Function in Subjects Exposed to Chernobyl Fallout during Childhood: Evidence for a Transient Radiation-Induced Elevation of Serum Thyroid Antibodies without an Increase in Thyroid Autoimmune Disease. J.Clin.Endocrinol. Metab, 2008, 93:2729-2736.
[34] Betterle C, Callegari G,Presotto F, et al.Thyroid autoantibodies: A good marker for the study of symptomless autoimmune thyroiditis. Acta Endocrinol, 1987, 114:321-327.
[35] Bermann M, Magee M, Koenig RJ,et al. Differential autoantibody responses to thyroid peroxidase in patients with Graves' disease and Hashimoto's thyroiditis. J. Clin. Endocrinol. Metab, 1993, 77:1098-1101.
[36] Atherton MC, McLachlan SM, Pegg CA, et al.Thyroid autoantibody synthesis by lymphocytes from different lymphoid organs:fractionation of B cells on density gradients. Immunology,1985,55(2):271-279.
[37] Frank J. Twarog, Noel R. J.The Production of Thyroid Autoantibodies in Mice. Immunol, 1968, 101:242-250.
[38] Brand O J, Barrett J C, Simmondsl M J, et al. Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum.Mol. Genet, 2009, 18:1704-1713.
[39] Sanders J, Oda Y.Roberts S,et al.The Interaction of TSH Receptor Autoantibodies with 125'-Labelled TSH Receptor. J. Clin. Endocrinol.Metab, 1999, 84:3797-3802.
[40] Jaume J C, Ayumu Kakinuma A, Gregorio D, et al. McLachlan. Thyrotropin Receptor Autoantibodies in Serum Are Present at Much Lower Levels Than Thyroid Peroxidase Autoantibodies: Analysis by Flow Cytometry. J. Clin.Endocrinol. Metab, 1997, 82:500-507.
[41] Elies R, Ferrari I.Wallukat G, et al. Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas' disease. J. Immunol, 1996,157:4203-4211.
[42] Kawaji N, Yoshida A, Motoyashiki T, et al.Anti-leptin receptor antibody mimics the stimulation of lipolysis induced by leptin in isolated mouse fat pads. J. Lipid Res, 2001, 42:1671-1677.
[43] Metcalfe R, Jordan N, Watson P, et al. Demonstration of Immunoglobulin G, A, and E Autoantibodies to the Human Thyrotropin Receptor Using Flow Cytometry. J. Clin. Endocrinol. Metab, 2002,87:1754-1761.
[44] Beekman S, Steens S, Buchem MA,et al.Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus, 2007, 16:329-334..
[45] Hubel C A, Wallukat G, Wolf M, et al.Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia. Hypertension, 2007, 49:612-617.
[46] LaMarca B, Wallukat G, Llinas M, et al. Autoantibodies to the Angiotensin Type I Receptor in Response to Placental Ischemia and Tumor Necrosis Factor αin Pregnant Rats. Hypertension, 2008, 52:1168-1172.
[47] Satoh T, Kimura K, Okano Y, et al. Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension. Rheumatology, 2005, 44:192-196.
[48] Qing Y, Zhou J G, Yuan G. Systemic lupus erythematosus presenting as hypoglycaemia with insulin receptor antibodies and insulin autoantibodies. Lupus, 2009, 18:457-459.
[49] Liliane F J, Andreea I F, Luc R, et al. Markedly Different Pathogenicity of Four Immunoglobulin G Isotype-Switch Variants of an Antiery-throcyte Autoantibody Is Based on Their Capacity to Interact In Vivo with the Low-Affinity Fc(?) Receptor III. J. Exp. Med,2000,191 :1293.
[50]Kov(?)cs L,Marczinovits I,Gy(o|¨)rgy A,et al.Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3213-228 in primary SjSgren’s syndrome.Rheumatology,2005,44:1021-1025.
[51]Husebye E S,Sthoeger Z ,Dayan M,et al.Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus.Ann Rheum Dis,2005,64:1210-1213.
[52]孙铀，张凤山，张志毅．系统性红斑狼疮患者C1q受体和C1q抗体的表达及其与发病相关性的研究．中华风湿病学杂志．2007，6(11)：352-355．
[53]Gottumukkala RV,Gavalas NG,Akhtar S,et al.Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients.Lab Invest,2006,86(8):781-789.
[54]Silvia S B,Mariarosaria S,Federica B,et al.Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis.N.Engl.J.Med,2006,354:2667-2676.
[55]Fredrik W,Yunying Ch,Timo P,et al.Class A scavenger receptors regulate tolerance against apoptotic cells,and autoantibodies against these receptors are predictive of systemic lupus.J.Exp.Med,2007,204:2259-2265.
[56]Zhang L,Hu D,Li J,et al.Autoantibodies against the myocardial betal-adrenergic and M2-muscarinic receptors in patients with congestive heart failure.Chin Med J(Engl),2002,115(8):1127-1131.
[57]Maria I L,Saiju J,Stuart V,etal.IgGl antibodies to acetylcholine receptors in ‘seronegative’ myastheniagravis.Brain,2008,131(7):1940-1952.
[58]KovScs L,Marczinovitsl I,Gy6rgy A,et al.Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3213 - 228 in primary Sj(o|¨)gren’s syndrome.Rheumatology,2005,44(8):1021-1025.
[59]Stephanie P,Zhou.Y X,Nishiyama Y,et al.Autoantibodies to the epidermal growth factor receptor in systemic sclerosis,lupus,and autoimmune mice.FASEB J,2003,17:136.
[60]Yokotal S,Minota S,Fujiil N.Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors International Immunology 2006 18(4):573-580.
[61]张之南，沈悌主编．血液病诊断及疗效标准．第三版，北京：科学技术出版社，2007．
[62]邵宗鸿．免疫性血细胞减少症的分类及治疗原则．中国实用内科学杂志，2006，26(7)：481-482．
[63]付蓉．免疫相关性全血细胞减少症的诊断及治疗．中国实用内科学杂志，2006，26(7)：492-495．
[64]邢佩霓，韩秀，杨娣娣等．人卵黄囊造血的探讨．细胞生物学杂志，1999，21：37-39．
[65]曾风华，沈柏均，王红美，等．胎盘造血功能的初步研究．中华血液学杂志，2000，6：291—293．
[66]Maaike A,Kooij V D,Elisabeth M,et al.Morand.HumanMonocyte-Derived Macrophages Express an(d)120-kD Ox-LDL Binding Protein With Strong Identity to CD68.Arteriosc]er.Thromb.Vasc.Biol,1997,17:3107 -3116.
[67]Notsu E,Sonoda Y,Sasaki KA.histological study and three-dimensional reconstruction of F4/80-positive reticular cells and macrophages at the onset of murine bone marrow hematopoiesis Kaibogaku Zasshi, 2007, 82:53-60.
[68] Yokoyama T,Etoh T, Kitagawa H,et al. Migration of erythroblastic islands toward the sinusoid as erythroid maturation proceeds in rat bone marrow. J Vet Med Sci,2003, 65:449-452.
[69] Sadahira Y, Yoshino T, Monobe Y.Very late activation antigen 4-vascular cell adhesion molecule 1 interaction is involved in the formation of erythroblastic islands. J. Exp. Med. 1995,181:411-415.
[70] Rosemblatt M, Vuillet-Gaugler MH, Leroy C, et al. Coexpression of two fibronectin receptors,VLA-4 and VLA-5,by immature human erythroblastic precursor cells.J.Clin Invest. 1991,87:6-11.
[71] Elices MJ, Osborn Y, Tanada Y. et al.VCAM-1 on activated endothelium interacts with leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.Cell.1990, 60:577-584.
[72] Crocker P R, Werb Z., Gordon S.,et al. Ultrastructural localization of a macrophage-restricted sialic acid binding hemagglutinin, SER,in macrophage-hematopoietic cell clusters. Blood, 1990, 76:1131-1138.
[73] Soni S, Bala S, Gwynn B, et al. Absence of erythroblast macrophage protein (Emp) leads to failure of erythroblast nuclear extrusion.Epub,2006, 281:20181-20189.
[74] Soni S,Hanspal, M. Cellular Localization and Developmental Expression of Emp Correlates with Its Role in Erythroblastic Island Formation. Blood (ASH Annual Meeting Abstracts) 2006 108:Abstract 537.
[75] Lee G, Lo A, Short SA, et al. Targeted gene deletion demonstrates that cell adhesion molecule ICAM-4 is critical for erythroblastic island formation. Blood, 2006, 108:2064-2071.
[76] Ihanusl E, Uotilal L, Toivanenl A, et al. Red-cell ICAM-4 is a ligand for the monocyte/macrophage integrin CDllc/CD18: characterization of the binding sites on ICAM-4. Blood, 2007, 109:802-810.
[77] Li D, Wang GY, Liu ZF,et al.Macrophage-associated erythropoiesis and lymphocytopoiesis in mouse fetal liver: ultrastructural and ISH analysis. Cell Biol Int,2004,28:457-461.
[78] Chasis JA. Erythroblastic islands: specialized microenvironmental niches for erythropoiesis. Curr Opin Hematol,2006,13:137-141.
[79] Erythroblastic island. Blood, 2004, 104:2622.
[80] Bernard J. The erythroblastic island: Past and future. Blood Cells,1991,17:5-10.
[81] Kawane, K, Fukuyama, H, Kondoh, G, et al. Requirement of DNase II for Definitive Erythropoiesis in the Mouse Fetal Liver.Science,2001,292:1546-1549.
[82] Krieser, R. J, MacLea, K. S, Longnecker, D. S, et al. Deoxyribonuclease IIalpha is required during the phagocytic phase of apoptosis and its loss causes perinatal lethality Cell Death. Differ, 2002, 9:956-962.
[83] Bonnesen,B,Orskov,C, Rasmussen S,et al.MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver.Blood,2005,106:3396-3404.
[84] Hanspal M, Hanspal JS.The association of erythroblasts with macrophages promotes erythroid proliferation and maturation:a 30-kD heparin-binding protein is involved in this contact. Blood.1994, 15, 84 (10): 3494-504.
[85]Tordjman R,Delaire S,Plou(e|¨)t J,et al.Erythroblasts are a source of angiogenic factors.Blood.2001,97:1968-1974.
[86]Crocker P.R.,Gordon S.Properties and distribution of a lectin-like hemagglutinin differentially expressed by murine stromal tissue macrophages.J.Exp.Med,1986,164:1862-1875.
[87]童向民，金洁宋菊贞，等．骨髓红系造血岛的形念观察及其临床意义．中华检验医学杂志，2003，26：277-279．
[88]沈关心周汝麟主编．现代免疫学实验技术．第二版．武汉：湖北科学技术出版社，2002，414-416．
[89]龚非力主编．医学免疫学．第二版，北京：科学技术出版社，2004：171-174．
[90]吴玉章等译．基础免疫学(上，下册)／(美)保罗(Paul，W．E)编著；北京：科学出版社，2003，7：585 599．
[91]免疫平衡研究及其临床意义赵武述编著，北京：科学出版社，2005：122-132．
[92]医学免疫学．潘建平，邵传森主编．杭州：浙江大学出版社，2006．8：152．
[93]Coutelier JP,Detalle L,Musaji A,et al.Two-step mechanism of virus-induced autoimmune hemolytic anemia.Ann N Y Acad Sci,2007,1109:151-157.
[94]YoonJW,JunHS.Autoimmune destruction of pancreatic beta cells .Am J Ther.2005,12(6):580-591.
[95]Huh YO,Liu FJ Rogge K,et al.Positive direct antiglobulin test and high seruu immunoglobulin G values.Am J Cli path,1988,90:179-182.
[96]刘鸿，邵宗鸿，付蓉，等．骨髓单个核细胞Coombs试验阳性免疫相关性血 细胞减少症72例临床分析．第2版．中国实用内科学杂志，2007，27(16)：1270-1273．
[97] Nils G, Morgenthaler, Su C H, et al. Stimulating and Blocking Thyroid-Stimulating Hormone (TSH) Receptor Autoantibodies from Patients with Graves' Disease and Autoimmune Hypothyroidism Have Very Similar Concentration, TSH Receptor Affinity, and Binding Sites. J. Clin. Endocrinol.Metab, 2007, 92:1058-1065.
[98] Husa P, Chalupa P, Stroblova H, et al. Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients.Acta Virol, 2001, 45(1):7-ll.
[99] Waterman SA, Gordon TP,Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum,2000,43(7): 1647-1654.
[100]Lake DF, Schluter SF, Wang E, et al. Autoantibodies to the α/β T-Cell Receptors in Human Immunodeficiency Virus Infection: Dysregulation and Mimicry. PNAS,1994, 91:10849-10853.
[101] Marchalonis JJ, Lake DF, Schluter SF,et al. Autoantibodies against peptide-defined epitopes of T-cell receptors in retrovirally infected humans and mice.Adv Exp Med Biol, 1995,383:211-222.
[102] Basil R, Gregorio D, Chazenbalk, et al.The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies.Endocr. Rev, 1998, 19:673-716.
[1]邢佩霓，韩秀，杨娣娣等．人卵黄囊造血的探讨．细胞生物学杂志，1999，21：37-39．
[2]曾风华，沈柏均，王红美，等．胎盘造血功能的初步研究．中华血液学杂志，2000，6：291—293．
[3]Notsu E,Sonoda Y,Sasaki KA.histological study and three-dimensional reconstruction of F4/80-positive reticular cells and macrophages at the onset of murine bone marrow hematopoiesis Kaibogaku Zasshi,2007,82:53-60.
[4]Yokoyama T,Etoh T,Kitagawa H,et al.Migration of erythroblastic islands toward the sinusoid as erythroid maturation proceeds in rat bone marrow.J Vet Med Sci,2003,65:449-452.
[5]Yokoyama T,Etoh T,Kitagawa H,et al.Migration of erythroblastic islands toward the sinusoid as erythroid maturation proceeds in rat bone marrow.J Vet Med Sci,2003,65:449-452.
[6]Sadahira Y,Yoshino T,Monobe Y.Very late activation antigen 4-vascular cell adhesion molecule 1 interaction is involved in the formation of erythroblastic islands.J.Exp.Med.1995,181:411 - 415.
[7]Rosemblatt M,Vuillet-Gaugler MH,Leroy C,et al.Coexpression of two fibronectin receptors,VLA-4 and VLA-5,by immature human erythroblastic precursor cells.J.Clin Invest.1991,87:6-11.
[8]Elices MJ,Osborn Y,Tanada Y.et al.VCAM-1 on activated endothelium interacts with leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.Cell 1990;60:577- 584.
[9]Soni S,Bala S,Gwynn B,et al.Absence of erythroblast macrophage protein(Emp)leads to failure of erythroblast nuclear extrusion.Epub,2006,281:20181-20189.
[10]Soni S ,Hanspal,M.Cellular Localization and Developmental Expression of Emp Correlates with Its Role in Erythroblastic Island Formation. Blood (ASH Annual Meeting Abstracts) 2006 108: Abstract 537.
[11] Lee G, Lo A, Short SA, et al. Targeted gene deletion demonstrates that cell adhesion molecule ICAM-4 is critical for erythroblastic island formation. Blood,2006, 108:2064-2071.
[12] Ihanusl E,Uotilal L, Toivanenl A,et al. Red-cell ICAM-4 is a ligand for the monocyte/macrophage integrin CD11c/CD18: characterization of the binding sites on ICAM-4. Blood,2007,109:802-810.
[13] Li D, Wang GY, Liu ZF,et al.Macrophage-associated erythropoiesis and lymphocytopoiesis in mouse fetal liver: ultrastructural and ISH analysis. Cell Biol Int,2004, 28:457-461.
[14] Chasis JA. Erythroblastic islands: specialized microenvironmental niches for erythropoiesis. Curr Opin Hematol, 2006, 13:137-141.
[15] Erythroblastic island.Blood, 2004, 104:2622.
[16] Bernard J. The erythroblastic island: Past and future. Blood Cells, 1991, 17:5-10.
[17] Kawane, K, Fukuyama, H, Kondoh, G, et al. Requirement of DNase II for Definitive Erythropoiesis in the Mouse Fetal Liver.Science,2001,292:1546-1549
[18] Krieser,R.J,MacLea,K.S,Longnecker,D.S,et al.Deoxyribonuclease IIalpha is required during the phagocytic phase of apoptosis and its loss causes perinatal lethality Cell Death. Differ,2002,9:956-962.
[19] Bonnesen,B,Orskov,C,Rasmussen S,et al.MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver. Blood, 2005, 106: 3396-3404.
[20] Iavarone,A,King,E.R,Dal,X,et al.Retinoblastoma promotes definitive erythropoi--esis by repressing Id2 in fetal liver macrophages. Nature,2004,432: 1040-1045.
[21] Sathyanarayanal P,Madhu P,Menonl,et al.Erythropoietin modulation of podocalyxin and a proposed erythroblast niche.Blood,2007,110:509-518.
[22]Spike T B,Dibling C B,Macleod F K.Hypoxic stress underlies defects in erythroblast islands in the Rb null mouse.Blood,2007,0:blood-2007-01-069104vl.
[23]Liu XS,Li XH,Wang Y,et al.Disruption of palladin leads to defects in definitive erythropoiesis by interfering erythroblastic island formation in mouse fetal liver.Blood,2007,110:870-876.
[24]童向民，金洁宋菊贞，等。骨髓红系造血岛的形念观察及其临床意义．中华检验医学杂志,2003，26：277-279．
[25]邵宗鸿，付蓉．免疫相关性血细胞减少症一种新认知的疾病(上)．中国医刊，2005，40：5-8．
[26]邵宗鸿，付蓉．免疫相关性血细胞减少症一种新认知的疾病(下)．中国医刊，2005，4 1：6-9．
[1]吴玉章等译．基础免疫学(上，下册)／(美)保罗(Paul，W．E)编著；北京：科学出版社，2003，7：585-599．
[2]免疫平衡研究及其临床意义赵武述编著， 北京：科学出版社，2005：122-132．
[3]医学免疫学．潘建平，邵传森主编．杭州：浙江大学出版社，2006．8：152．
[4]高晓明主编．医学免疫学基础．北京：北京大学医学出版社．2001，15．
[5]Auffray C,Fogg D,Garfa M,et al.Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior.Science,2007,317(5838):666-670.
[6]Liu H,Shi B,Huang CC,et al.Transcriptional diversity during monocyte to macrophage differentiation.Immunol Lett,2008 Jan 22 [Epub ahead of print].
[7]Cairns AP,Crockard AD,Bell AL.The CD14+ CD16+ monocyte subset in rheumatoid arthritis and systemic lupus erythematosus.Rheumatol Int,2002,21:189-192.
[8]Martynova TV,Aleksiuk LI.Functional activity of the peritoneal macrophages in mice with concanavalin A-induced hepatitis.Fiziol Zh,2007,53:47-52.
[9]Tas SW,Quartier P,Botto M,et al.Macrophages from patients with SLEandrheumatoidarthritis have defective adhesion in vitro,while only SLE macrophages have impaired uptake of apoptotic cells.Ann Rheum Dis,2006,65:216-221.
[1O]Ren Y,Tang J,Mok MY,et al.Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus.Arthritis Rheum, 2003,48:2888-2897.
[11] Shoshan Y, Shapira I, Toubi E, et al. Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: relevance to in vitro impairment of interaction with iC3b-opsonized apoptotic cells. J Immunol, 2001, 167:5963-5969.
[12] Bijl M, Reefman E, Horst G, et al. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis,2006, 65:57-63.
[13] Grevink ME, Horst G, Limburg PC, et al.Levels of complement in sera from inactive SLE patients, although decreased, do not influence in vitro uptake of apoptotic cells. J Autoimmun, 2005,24:329-336.
[14] Allina J, Stanca CM, Garber J, et al.Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. J Autoimmun, 2007 17 [Epub ahead of print].
[15] Reefman E, Horst G, Nijk MT,et al. Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies inhibits their uptake via an Fcgamma receptor-dependent mechanism. Arthritis Rheum,2007,56:3399-3411.
[16] O'Neill HC, Quah BJ. Exosomes secreted by bacterially infected macrophages are proinflammatory. Sci Signal, 2008, 1:pe8.
[17] Coutelier JP, Detalle L, Musaji A, et al. Two-step mechanism of virus-induced autoimmune hemolytic anemia. Ann N Y Acad Sci, 2007, 1109:151-157.
[18] Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.Am J Physiol Renal Physiol,2008 13 [Epub ahead of print].
[16]Sodhi A,Tripathi A.Prolactin and growth hormone induce differential cytokine and chemokine profile in murine peritoneal macrophages in vitro:involvement of p-38 MAP kinase,STAT3 and NF-kappaB.Cytokine,2008,41:162-173.
[20]Tripathi A,Sodhi A.Prolactin-induced production of cytokines in macrophages in vitro involves JAK/STAT and JNK MAPK pathways.Int Immunol,2008,20:327-336.
[21]Zhu B,Suzuki K,Goldberg HA,et al.Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors:evidence of a role for an intracellular form of osteopontin.J Cell Physiol,2004,198:155-167.
[22]Das R,Burke T,Plow EF Histone H2B as a functionally important plasminogen receptor on macrophages.Blood,2007,110:3763-3772.
[23]Sinha S,Kaler LJ,Proctor TM,et al.IL-13-Mediated Gender Difference in Susceptibility to Autoimmune Encephalomyelitis.J Immunol,2008,180:2679-2685.
[24]Wang H,Madariaga ML,Wang S,et al.Lack of CD47 on nonhematopoietic cells induces split macrophage tolerance to CD47null cells.Proc Natl Acad Sci U S A,2007,104:13744-13749.
[25]邢莉民，邵宗鸿，付蓉，等，自身免疫性血细胞减少症患者骨髓CD5+B细胞数量变化及其临床意义．中国实用内科杂志2005．25(11)：994-996．
[26]高晓明．医学免疫学基础．第一版．北京：北京大学医学出版社，2005．138-154．
[27]Toriani-Terenzi C,Fagiolo E.Th2 cytokine role in autoimmune haemolytic anaemia(AIHA)pathogenesis.Panminerva Ned.2001,43(1)
[28] Toriani-Terenzi C, Pozzetto U, Bianchi M, et al Cytokine network in autoimmune haemolytic anaemia: new probable targets for therapy. Cancer Detect Prev. 2002, 26(4):292-298.
[29] Fagiolo E, Toriani-Terenzi C. Th1 and Th2 cytokine modulation by IL—10/IL—12 imbalance in autoimmune haemolytic anaemia (AIHA).Autoimmunity. 2002,35(1):39-44.
[30] Ahn, Eckhard Podack, Wenche Jy. et al. Soluble CD30 (sCD30),a Marker of Th2 Polarization, Is Elevated in Patients with Autoimmune Hemolytic Anemia (AIHA) but Not with Idiopathic Thrombocytopenia (ITP).Eugene R. Blood (ASH Annual Meeting Abstracts),2005, 106:1248.
[31] Lim HW, Hillsamer P, Banham AH, et al. Cutting edge :direct suppression of B cells by CD4+CD25+ regulatory T cells. J Immunol,2005,175(7):4180-4183.
[32] Mqadmi A, Zheng X, Yazdanbakhsh K.CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. Blood.2005 ,105(9): 3746-3748.
[33] Okazaki T, Iwai Y,Honjo T.New regulatory co-receptors:inducible costimulator and PD-1.Curr Opin Immunol.2002, 14(6):779-782.
[34] Iwai Y, Terawaki S, Ikegawa M, et al.PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med,2003,198(1):39-50.
[35] Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol, 2001. 19:275-290.
[36] Pritchard NR, Smith KG. B cell inhibitory receptors and autoimmunity.immunology, 2003, 108(3):263-273.
[37]Davis RS,Ehrhardt GR,Leu MC,et al.An extended family of Fc receptor relatives.Eer J Immunol,2005,35(3):674-680.
[38]Chaim O.Jacob ,Luminita Pricop,Chaim Putterman,et al.Paucity of Clinical Disease despite Serological Autoimmunity and Kidney Pathology in Lupus-Prone New Zealand Mixed 2328 Mice Deficient in BAFF.The Journal of Immunology,2006,177:2671-2680.
[39]Straus SE,Sneller M,Lenardo MJ,et al.An inhereited disorder of lymphocyte apoptosis:the autoimmune lymphoproliferative syndrome.Ann intern Med,1999.130(7):591-601.
[40]Watanabe N,Ikuta K,Nisitani S,et al.Activation and differentiation of autoreactive B-1 cells by interleukin 10 induce autoimmune hemolytic anemia in Fas-deficient antierythrocyte immunoglobulin transgenic mice.J Exp Med.2002 ,196(1):141-146.
[41]Suzuki A,Sasaki T,Mak TW,et al.Functional analysis of the tumour suppressor gene PTEN in murine B cells and keratinocytes.Biochem Soc Trans,2004,(32Pt):362-365.
[42]Brown KS,Blair D,Reid SD,et al.FcgammaR Ⅱ b-mediated negative regulation of BCR signaling is associated with the recruitment of the MAPkinase-phosphatase,Pac-l,and the 3’ -inositol phosphatase,PTEN.Cell Signal,2004,16(1):71-80.
[43]张欣，高清平，王琼玉，等．B淋巴细胞的周期蛋白表达及周期分布在特发性血小板减少性紫癜发病机制中的意义．中华血液学杂志，2006．27(9)： 630-631．
[44]Hoffman PC.Immune hemolytic anemia--selected topics.Hematology Am Soc Hematol Educ Program.2006:3-8.
[45]Toriani-Terenzi C,Fagio]o E.Th2 cytokine role in autoimmune haemolytic anaemia(AIHA)pathogenesis.Panminerva Med.2001,3(1):1-5.
[46]Toriani-Terenzi C,Pozzetto U,Bianchi M,et al Cytokine network in autoimmune haemolytic anaemia:new probable targets for therapy.Cancer Detect Prev.2002,26(4):292-298.
[47]Mqadmi A,Zheng X,Yazdanbakhsh K.CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia.Blood.2005,5(9):3746-3748.
[48]付蓉，邵宗鸿，刘鸿，等．与免疫相关的全血细胞减少患者骨髓造血细胞自身抗体的研究．中华血液学杂志，2003，4(4)：177—180．
[49]邵宗鸿，付蓉．免疫相关性血细胞减少症—一种新认知的疾病(上)．中国医刊，2005．40(1)：5-8．
[50]邵宗鸿，付蓉．免疫相关性血细胞减少症—一种新认知的疾病(下)．中国医刊，2005．40(2)：6-9．
[51]付蓉，邵宗鸿，和虹，等．免疫相关性全血细胞减少症患者骨髓B淋巴细胞数量及凋亡相关蛋白水平．中华血液学杂志，2002．23(5)：236-238．
[52]侯明，秦平．特发性血小板减少性紫癜的基础与临床进展．第九次全国血液学年会学术会议，2006．1 0：55-59．
[53]McMillan R,Lopez-Dee J,Bowditch.Clonal restriction of platelet associated anti-GP autoantibodies in patients with chronic ITP.Thromb Haemost,2001,85:821-823.
[54]Roark JH,Bussel JB,Cines DB,et al.Genetic analysis of autoanti -bodies in idiopathic thrombocytopenic purura reveals evidence of clona]expansion and somatic mutation.Blood,2002,100:1388-1398.
[55]Mei Chang,Peggy A.Nakagawa,etal.Immune thrombocytopenic purpura(ITP)plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro Blood,2003,02:887-895.
[56]石艳，侯明，彭军，等．自身免疫性血小板减少性紫癜特异性自身抗体的克隆性分析．第九届全国实验血液学会议论文摘要汇编．2003．196-197．
[57]MihaFurlan,RodolfoRobles,MiriamGalbusera,etal.vonWillebrand Factor-Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic-Uremic Syndrome.N.Engl.J.Med,1998,39:1578-584.
[58]Han-Mou Tsai,Eric Chun-Yet Lian.Antibodies to von Willebrand Factor-Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura.N.Engl.J.Med,998,39:1585-594.
[59]Bux J,Behrens G,Jaeger G,etal.Diagnosis and clinical course ofautoimmuneneutropeniaininfancy:analysis of 240 cases.Blood,1998,91(1):181-186.
[60]袁燕，谢毅．全血法流式细胞术检测中性粒细胞抗体方法建立及临床应用．诊断理论与实践．2004．3(6)：409-411．
[2]Wimazal F,Fonatsch C,Thalhammer R,et al .Idiopathic cytopenia of undetermined significance(ICUS)versus low risk MDS:the diagnostic interface.Leuk Res.2007,31(11):1461-1468.
[3]和虹，邵宗鸿，刘鸿等．与异常免疫相关的全血细胞减少症．中华血液学杂志，2001，22：79-82．
[4]Hong He,Zonghong Shao,Rong Fu,et al.Hemocytopenia related to immunity detected by modified Coombs test for measuring autoantibody of bone marrow mononuclear cells.BLOOD,2002,100:136b.
[5]张之南，沈悌，主编。血液病诊断及疗效标准．第三版，北京：科学技术出版社，2007．
[6]和虹，邵宗鸿，曹增等．骨髓单个核细胞抗人球蛋白分型实验．中华血液学杂志，2000，21：550-551．
[7]和虹，邵宗鸿．改良直接抗人球蛋白试验的进展．中华检验医学杂志，2001，24(5)：313-315．
[8]RongFu,ZonghongShao,HongLiu,etal.Type,Distribution,andClinical Significance of Auto-antibody on Bone Marrow Hematopoietic Cells in Patients with Immuno-Related Pancytopenia.BLOOD,2002,100:136b.
[9]J acqueline H,Audrey L,Joel A,et al.Regulation of differentiation of Peritoneal B-la(CD5+)B cell.J Immunol,1995,154:5630-5636.
[10]Loza E,Tintue T,Sanchez-Ibarrola A.CD5 and CD23 expression on B cells in peripheral blood and synovial fluid of rheumatoid arthritis patients:relationship with interleukin-4、soluble CD23 and tumor necrosis factor alpha levels.Rheumatology,1999,38:325-328.
[11]Xing LM,Shao ZH,Fu R,et al.Subtypes of B lymphocytes in patients with autoimmune hemocytopenia.Chin Med Sci J.2007,22(2):128-131.
[12]付蓉，邵宗鸿，和虹等．免疫相关性全血减少症患者骨髓B淋巴细胞数量及凋亡相关蛋白水平．中华血液学杂志，2002，23：236-238．
[13]Rong Fu,Zonghong Shao,Hong he,et al.The quantities and apoptosis -related protein levels of B lymphocytes in patients with immunorelated pancytopenia.BLOOD,2002,100:171b.
[14]Fu R,Shao ZH,Liu H,et al.Role of B lymphocyte and its subpopulations in pathogenesis of immunorelated pancytopenia.Chin Med Sci J.2007,22(3):199-202.
[15]Siszar A,Nagy GY,Gergely P,et al.Increased IFN-γ,IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cell(PBMC)from patients with SLE.Clin Exp Immunol,2002,122:464-470.
[16]付蓉，邵宗鸿，刘鸿等．与免疫相关的血细胞减少患者骨髓造血祖细胞增殖功能测定及T辅助淋巴细胞功能观察．中华血液学杂志，2004，25：213-216．
[17]邵宗鸿，付蓉．免疫相关性血细胞减少症一种新认知的疾病(上)．中国医刊，2005，40：5-8．
[18]邵宗鸿，付蓉．免疫相关性血细胞减少症一种新认知的疾病(下)．中国医刊，2005，41：6-9．
[19]Julius U,Patzak A,Schaich M,Ehninger G,Kamin G Immune thrombocyto -penia,anemia and leukopenia during pregnancy.Successful therapy with extracorporeal immunoadsorption Dtsch Med Wochenschr. 1997, 122(8): 220-224.
[20] Favara BE,Jaffe R, Egeler RM.Macrophage activation and hemophago—cytic syndrome in langerhans cell histiocytosis:report of 30 cases. Pediatr Dev Pathol. 2002, 5(2):130-140.
[21] Lonceint J, Sassolas B, Lefur JM, Guillet G, Leroy JP. Panniculitis and macrophage activation syndrome in a child with lupus erythematosus.Ann Dermatol Venereol.2001, 128(12):1339-1342.
[22] Kelaidi C, Buturuga A, Dousset B, Calmus Y, Dreyfus F, Bouscary D.Autoimmune pancytopenia as an early complication of liver transplantation:report of one case. Leuk Lymphoma.2004,45(9):1951-1953.
[23] Deji N, Sugimoto T, Fujimoto T, Aoyama M, Takeda N, Sakaguchi M, Uzu T,Kashiwagi A. Emergence of panniculitis and haemophagocytic syndrome in a patient with chronic systemic lupus erythematosus. Lupus.2007, 16(5): 363-3655.
[24] Coutelier JP, Detalle L, Musaji A, et al.Two-step mechanism of virus-induced autoimmune hemolytic anemia. Ann N Y Acad Sci,2007,1109:151-157.
[25] Tesch GH. MCP-1/CCL2:a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.Am J Physiol Renal Physiol, 2008,13 [Epub ahead of print].
[26] Ghee J Y, Han D H, Song H K, et al.The role of macrophage in the pathogenesis of chronic cyclosporine nephropathy. Nephrol.Dial.Transplant, 2008, 23:4061-4069.
[27] Voskoboynik A, Rinkevich B, Weiss A, et al. Macrophage involvement for successful degeneration of apoptotic organs in the colonial urochordate Botryllus schlosseri. J. Exp.Biol, 2004, 207:2409-2416.
[28] Jo S K, Sung S A, Cho W Y, et al. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol.Dial. Transplant,2006,21:1231-1239.
[29] Kunisch E, Fuhrmann R,Roth A, et al. Macrophage specificity of three anti-CD68 monoclonal antibodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. Ann Rheum Dis, 2004, 63:774-784.
[30] Sawhney S, Woo P, Murray K J. Macrophage activation syndrome:a potentially fatal complication of rheumatic isorders.Arch.Dis.Child, 2001,85:421-426.
[31] Mevorach D, Mascarenhas J O, Gershov D, et al. Complement-dependent Clearance of Apoptotic Cells by Human Macrophages. J. Exp. Med, 1998,188:2313.
[32] Thomas E.Hamilton, Scott D,Lynn O,et al. Thyrotropin Levels in a Population with No Clinical, Autoantibody, or Ultrasonographic Evidence of Thyroid Disease:Implications for the Diagnosis of Subclinical Hypothyroidism. J. Clin. Endocrinol. Metab,2008,93:1224-1230.
[33] Agate L, Mariotti S, Elisei R, et al.Thyroid Autoantibodies and Thyroid Function in Subjects Exposed to Chernobyl Fallout during Childhood: Evidence for a Transient Radiation-Induced Elevation of Serum Thyroid Antibodies without an Increase in Thyroid Autoimmune Disease. J.Clin.Endocrinol. Metab, 2008, 93:2729-2736.
[34] Betterle C, Callegari G,Presotto F, et al.Thyroid autoantibodies: A good marker for the study of symptomless autoimmune thyroiditis. Acta Endocrinol, 1987, 114:321-327.
[35] Bermann M, Magee M, Koenig RJ,et al. Differential autoantibody responses to thyroid peroxidase in patients with Graves' disease and Hashimoto's thyroiditis. J. Clin. Endocrinol. Metab, 1993, 77:1098-1101.
[36] Atherton MC, McLachlan SM, Pegg CA, et al.Thyroid autoantibody synthesis by lymphocytes from different lymphoid organs:fractionation of B cells on density gradients. Immunology,1985,55(2):271-279.
[37] Frank J. Twarog, Noel R. J.The Production of Thyroid Autoantibodies in Mice. Immunol, 1968, 101:242-250.
[38] Brand O J, Barrett J C, Simmondsl M J, et al. Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum.Mol. Genet, 2009, 18:1704-1713.
[39] Sanders J, Oda Y.Roberts S,et al.The Interaction of TSH Receptor Autoantibodies with 125'-Labelled TSH Receptor. J. Clin. Endocrinol.Metab, 1999, 84:3797-3802.
[40] Jaume J C, Ayumu Kakinuma A, Gregorio D, et al. McLachlan. Thyrotropin Receptor Autoantibodies in Serum Are Present at Much Lower Levels Than Thyroid Peroxidase Autoantibodies: Analysis by Flow Cytometry. J. Clin.Endocrinol. Metab, 1997, 82:500-507.
[41] Elies R, Ferrari I.Wallukat G, et al. Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas' disease. J. Immunol, 1996,157:4203-4211.
[42] Kawaji N, Yoshida A, Motoyashiki T, et al.Anti-leptin receptor antibody mimics the stimulation of lipolysis induced by leptin in isolated mouse fat pads. J. Lipid Res, 2001, 42:1671-1677.
[43] Metcalfe R, Jordan N, Watson P, et al. Demonstration of Immunoglobulin G, A, and E Autoantibodies to the Human Thyrotropin Receptor Using Flow Cytometry. J. Clin. Endocrinol. Metab, 2002,87:1754-1761.
[44] Beekman S, Steens S, Buchem MA,et al.Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus, 2007, 16:329-334..
[45] Hubel C A, Wallukat G, Wolf M, et al.Agonistic Angiotensin II Type 1 Receptor Autoantibodies in Postpartum Women With a History of Preeclampsia. Hypertension, 2007, 49:612-617.
[46] LaMarca B, Wallukat G, Llinas M, et al. Autoantibodies to the Angiotensin Type I Receptor in Response to Placental Ischemia and Tumor Necrosis Factor αin Pregnant Rats. Hypertension, 2008, 52:1168-1172.
[47] Satoh T, Kimura K, Okano Y, et al. Lack of circulating autoantibodies to bone morphogenetic protein receptor-II or activin receptor-like kinase 1 in mixed connective tissue disease patients with pulmonary arterial hypertension. Rheumatology, 2005, 44:192-196.
[48] Qing Y, Zhou J G, Yuan G. Systemic lupus erythematosus presenting as hypoglycaemia with insulin receptor antibodies and insulin autoantibodies. Lupus, 2009, 18:457-459.
[49] Liliane F J, Andreea I F, Luc R, et al. Markedly Different Pathogenicity of Four Immunoglobulin G Isotype-Switch Variants of an Antiery-throcyte Autoantibody Is Based on Their Capacity to Interact In Vivo with the Low-Affinity Fc(?) Receptor III. J. Exp. Med,2000,191 :1293.
[50]Kov(?)cs L,Marczinovits I,Gy(o|¨)rgy A,et al.Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3213-228 in primary SjSgren’s syndrome.Rheumatology,2005,44:1021-1025.
[51]Husebye E S,Sthoeger Z ,Dayan M,et al.Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus.Ann Rheum Dis,2005,64:1210-1213.
[52]孙铀，张凤山，张志毅．系统性红斑狼疮患者C1q受体和C1q抗体的表达及其与发病相关性的研究．中华风湿病学杂志．2007，6(11)：352-355．
[53]Gottumukkala RV,Gavalas NG,Akhtar S,et al.Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients.Lab Invest,2006,86(8):781-789.
[54]Silvia S B,Mariarosaria S,Federica B,et al.Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis.N.Engl.J.Med,2006,354:2667-2676.
[55]Fredrik W,Yunying Ch,Timo P,et al.Class A scavenger receptors regulate tolerance against apoptotic cells,and autoantibodies against these receptors are predictive of systemic lupus.J.Exp.Med,2007,204:2259-2265.
[56]Zhang L,Hu D,Li J,et al.Autoantibodies against the myocardial betal-adrenergic and M2-muscarinic receptors in patients with congestive heart failure.Chin Med J(Engl),2002,115(8):1127-1131.
[57]Maria I L,Saiju J,Stuart V,etal.IgGl antibodies to acetylcholine receptors in ‘seronegative’ myastheniagravis.Brain,2008,131(7):1940-1952.
[58]KovScs L,Marczinovitsl I,Gy6rgy A,et al.Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3213 - 228 in primary Sj(o|¨)gren’s syndrome.Rheumatology,2005,44(8):1021-1025.
[59]Stephanie P,Zhou.Y X,Nishiyama Y,et al.Autoantibodies to the epidermal growth factor receptor in systemic sclerosis,lupus,and autoimmune mice.FASEB J,2003,17:136.
[60]Yokotal S,Minota S,Fujiil N.Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors International Immunology 2006 18(4):573-580.
[61]张之南，沈悌主编．血液病诊断及疗效标准．第三版，北京：科学技术出版社，2007．
[62]邵宗鸿．免疫性血细胞减少症的分类及治疗原则．中国实用内科学杂志，2006，26(7)：481-482．
[63]付蓉．免疫相关性全血细胞减少症的诊断及治疗．中国实用内科学杂志，2006，26(7)：492-495．
[64]邢佩霓，韩秀，杨娣娣等．人卵黄囊造血的探讨．细胞生物学杂志，1999，21：37-39．
[65]曾风华，沈柏均，王红美，等．胎盘造血功能的初步研究．中华血液学杂志，2000，6：291—293．
[66]Maaike A,Kooij V D,Elisabeth M,et al.Morand.HumanMonocyte-Derived Macrophages Express an(d)120-kD Ox-LDL Binding Protein With Strong Identity to CD68.Arteriosc]er.Thromb.Vasc.Biol,1997,17:3107 -3116.
[67]Notsu E,Sonoda Y,Sasaki KA.histological study and three-dimensional reconstruction of F4/80-positive reticular cells and macrophages at the onset of murine bone marrow hematopoiesis Kaibogaku Zasshi, 2007, 82:53-60.
[68] Yokoyama T,Etoh T, Kitagawa H,et al. Migration of erythroblastic islands toward the sinusoid as erythroid maturation proceeds in rat bone marrow. J Vet Med Sci,2003, 65:449-452.
[69] Sadahira Y, Yoshino T, Monobe Y.Very late activation antigen 4-vascular cell adhesion molecule 1 interaction is involved in the formation of erythroblastic islands. J. Exp. Med. 1995,181:411-415.
[70] Rosemblatt M, Vuillet-Gaugler MH, Leroy C, et al. Coexpression of two fibronectin receptors,VLA-4 and VLA-5,by immature human erythroblastic precursor cells.J.Clin Invest. 1991,87:6-11.
[71] Elices MJ, Osborn Y, Tanada Y. et al.VCAM-1 on activated endothelium interacts with leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.Cell.1990, 60:577-584.
[72] Crocker P R, Werb Z., Gordon S.,et al. Ultrastructural localization of a macrophage-restricted sialic acid binding hemagglutinin, SER,in macrophage-hematopoietic cell clusters. Blood, 1990, 76:1131-1138.
[73] Soni S, Bala S, Gwynn B, et al. Absence of erythroblast macrophage protein (Emp) leads to failure of erythroblast nuclear extrusion.Epub,2006, 281:20181-20189.
[74] Soni S,Hanspal, M. Cellular Localization and Developmental Expression of Emp Correlates with Its Role in Erythroblastic Island Formation. Blood (ASH Annual Meeting Abstracts) 2006 108:Abstract 537.
[75] Lee G, Lo A, Short SA, et al. Targeted gene deletion demonstrates that cell adhesion molecule ICAM-4 is critical for erythroblastic island formation. Blood, 2006, 108:2064-2071.
[76] Ihanusl E, Uotilal L, Toivanenl A, et al. Red-cell ICAM-4 is a ligand for the monocyte/macrophage integrin CDllc/CD18: characterization of the binding sites on ICAM-4. Blood, 2007, 109:802-810.
[77] Li D, Wang GY, Liu ZF,et al.Macrophage-associated erythropoiesis and lymphocytopoiesis in mouse fetal liver: ultrastructural and ISH analysis. Cell Biol Int,2004,28:457-461.
[78] Chasis JA. Erythroblastic islands: specialized microenvironmental niches for erythropoiesis. Curr Opin Hematol,2006,13:137-141.
[79] Erythroblastic island. Blood, 2004, 104:2622.
[80] Bernard J. The erythroblastic island: Past and future. Blood Cells,1991,17:5-10.
[81] Kawane, K, Fukuyama, H, Kondoh, G, et al. Requirement of DNase II for Definitive Erythropoiesis in the Mouse Fetal Liver.Science,2001,292:1546-1549.
[82] Krieser, R. J, MacLea, K. S, Longnecker, D. S, et al. Deoxyribonuclease IIalpha is required during the phagocytic phase of apoptosis and its loss causes perinatal lethality Cell Death. Differ, 2002, 9:956-962.
[83] Bonnesen,B,Orskov,C, Rasmussen S,et al.MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver.Blood,2005,106:3396-3404.
[84] Hanspal M, Hanspal JS.The association of erythroblasts with macrophages promotes erythroid proliferation and maturation:a 30-kD heparin-binding protein is involved in this contact. Blood.1994, 15, 84 (10): 3494-504.
[85]Tordjman R,Delaire S,Plou(e|¨)t J,et al.Erythroblasts are a source of angiogenic factors.Blood.2001,97:1968-1974.
[86]Crocker P.R.,Gordon S.Properties and distribution of a lectin-like hemagglutinin differentially expressed by murine stromal tissue macrophages.J.Exp.Med,1986,164:1862-1875.
[87]童向民，金洁宋菊贞，等．骨髓红系造血岛的形念观察及其临床意义．中华检验医学杂志，2003，26：277-279．
[88]沈关心周汝麟主编．现代免疫学实验技术．第二版．武汉：湖北科学技术出版社，2002，414-416．
[89]龚非力主编．医学免疫学．第二版，北京：科学技术出版社，2004：171-174．
[90]吴玉章等译．基础免疫学(上，下册)／(美)保罗(Paul，W．E)编著；北京：科学出版社，2003，7：585 599．
[91]免疫平衡研究及其临床意义赵武述编著，北京：科学出版社，2005：122-132．
[92]医学免疫学．潘建平，邵传森主编．杭州：浙江大学出版社，2006．8：152．
[93]Coutelier JP,Detalle L,Musaji A,et al.Two-step mechanism of virus-induced autoimmune hemolytic anemia.Ann N Y Acad Sci,2007,1109:151-157.
[94]YoonJW,JunHS.Autoimmune destruction of pancreatic beta cells .Am J Ther.2005,12(6):580-591.
[95]Huh YO,Liu FJ Rogge K,et al.Positive direct antiglobulin test and high seruu immunoglobulin G values.Am J Cli path,1988,90:179-182.
[96]刘鸿，邵宗鸿，付蓉，等．骨髓单个核细胞Coombs试验阳性免疫相关性血 细胞减少症72例临床分析．第2版．中国实用内科学杂志，2007，27(16)：1270-1273．
[97] Nils G, Morgenthaler, Su C H, et al. Stimulating and Blocking Thyroid-Stimulating Hormone (TSH) Receptor Autoantibodies from Patients with Graves' Disease and Autoimmune Hypothyroidism Have Very Similar Concentration, TSH Receptor Affinity, and Binding Sites. J. Clin. Endocrinol.Metab, 2007, 92:1058-1065.
[98] Husa P, Chalupa P, Stroblova H, et al. Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients.Acta Virol, 2001, 45(1):7-ll.
[99] Waterman SA, Gordon TP,Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum,2000,43(7): 1647-1654.
[100]Lake DF, Schluter SF, Wang E, et al. Autoantibodies to the α/β T-Cell Receptors in Human Immunodeficiency Virus Infection: Dysregulation and Mimicry. PNAS,1994, 91:10849-10853.
[101] Marchalonis JJ, Lake DF, Schluter SF,et al. Autoantibodies against peptide-defined epitopes of T-cell receptors in retrovirally infected humans and mice.Adv Exp Med Biol, 1995,383:211-222.
[102] Basil R, Gregorio D, Chazenbalk, et al.The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies.Endocr. Rev, 1998, 19:673-716.
[1]邢佩霓，韩秀，杨娣娣等．人卵黄囊造血的探讨．细胞生物学杂志，1999，21：37-39．
[2]曾风华，沈柏均，王红美，等．胎盘造血功能的初步研究．中华血液学杂志，2000，6：291—293．
[3]Notsu E,Sonoda Y,Sasaki KA.histological study and three-dimensional reconstruction of F4/80-positive reticular cells and macrophages at the onset of murine bone marrow hematopoiesis Kaibogaku Zasshi,2007,82:53-60.
[4]Yokoyama T,Etoh T,Kitagawa H,et al.Migration of erythroblastic islands toward the sinusoid as erythroid maturation proceeds in rat bone marrow.J Vet Med Sci,2003,65:449-452.
[5]Yokoyama T,Etoh T,Kitagawa H,et al.Migration of erythroblastic islands toward the sinusoid as erythroid maturation proceeds in rat bone marrow.J Vet Med Sci,2003,65:449-452.
[6]Sadahira Y,Yoshino T,Monobe Y.Very late activation antigen 4-vascular cell adhesion molecule 1 interaction is involved in the formation of erythroblastic islands.J.Exp.Med.1995,181:411 - 415.
[7]Rosemblatt M,Vuillet-Gaugler MH,Leroy C,et al.Coexpression of two fibronectin receptors,VLA-4 and VLA-5,by immature human erythroblastic precursor cells.J.Clin Invest.1991,87:6-11.
[8]Elices MJ,Osborn Y,Tanada Y.et al.VCAM-1 on activated endothelium interacts with leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site.Cell 1990;60:577- 584.
[9]Soni S,Bala S,Gwynn B,et al.Absence of erythroblast macrophage protein(Emp)leads to failure of erythroblast nuclear extrusion.Epub,2006,281:20181-20189.
[10]Soni S ,Hanspal,M.Cellular Localization and Developmental Expression of Emp Correlates with Its Role in Erythroblastic Island Formation. Blood (ASH Annual Meeting Abstracts) 2006 108: Abstract 537.
[11] Lee G, Lo A, Short SA, et al. Targeted gene deletion demonstrates that cell adhesion molecule ICAM-4 is critical for erythroblastic island formation. Blood,2006, 108:2064-2071.
[12] Ihanusl E,Uotilal L, Toivanenl A,et al. Red-cell ICAM-4 is a ligand for the monocyte/macrophage integrin CD11c/CD18: characterization of the binding sites on ICAM-4. Blood,2007,109:802-810.
[13] Li D, Wang GY, Liu ZF,et al.Macrophage-associated erythropoiesis and lymphocytopoiesis in mouse fetal liver: ultrastructural and ISH analysis. Cell Biol Int,2004, 28:457-461.
[14] Chasis JA. Erythroblastic islands: specialized microenvironmental niches for erythropoiesis. Curr Opin Hematol, 2006, 13:137-141.
[15] Erythroblastic island.Blood, 2004, 104:2622.
[16] Bernard J. The erythroblastic island: Past and future. Blood Cells, 1991, 17:5-10.
[17] Kawane, K, Fukuyama, H, Kondoh, G, et al. Requirement of DNase II for Definitive Erythropoiesis in the Mouse Fetal Liver.Science,2001,292:1546-1549
[18] Krieser,R.J,MacLea,K.S,Longnecker,D.S,et al.Deoxyribonuclease IIalpha is required during the phagocytic phase of apoptosis and its loss causes perinatal lethality Cell Death. Differ,2002,9:956-962.
[19] Bonnesen,B,Orskov,C,Rasmussen S,et al.MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver. Blood, 2005, 106: 3396-3404.
[20] Iavarone,A,King,E.R,Dal,X,et al.Retinoblastoma promotes definitive erythropoi--esis by repressing Id2 in fetal liver macrophages. Nature,2004,432: 1040-1045.
[21] Sathyanarayanal P,Madhu P,Menonl,et al.Erythropoietin modulation of podocalyxin and a proposed erythroblast niche.Blood,2007,110:509-518.
[22]Spike T B,Dibling C B,Macleod F K.Hypoxic stress underlies defects in erythroblast islands in the Rb null mouse.Blood,2007,0:blood-2007-01-069104vl.
[23]Liu XS,Li XH,Wang Y,et al.Disruption of palladin leads to defects in definitive erythropoiesis by interfering erythroblastic island formation in mouse fetal liver.Blood,2007,110:870-876.
[24]童向民，金洁宋菊贞，等。骨髓红系造血岛的形念观察及其临床意义．中华检验医学杂志,2003，26：277-279．
[25]邵宗鸿，付蓉．免疫相关性血细胞减少症一种新认知的疾病(上)．中国医刊，2005，40：5-8．
[26]邵宗鸿，付蓉．免疫相关性血细胞减少症一种新认知的疾病(下)．中国医刊，2005，4 1：6-9．
[1]吴玉章等译．基础免疫学(上，下册)／(美)保罗(Paul，W．E)编著；北京：科学出版社，2003，7：585-599．
[2]免疫平衡研究及其临床意义赵武述编著， 北京：科学出版社，2005：122-132．
[3]医学免疫学．潘建平，邵传森主编．杭州：浙江大学出版社，2006．8：152．
[4]高晓明主编．医学免疫学基础．北京：北京大学医学出版社．2001，15．
[5]Auffray C,Fogg D,Garfa M,et al.Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior.Science,2007,317(5838):666-670.
[6]Liu H,Shi B,Huang CC,et al.Transcriptional diversity during monocyte to macrophage differentiation.Immunol Lett,2008 Jan 22 [Epub ahead of print].
[7]Cairns AP,Crockard AD,Bell AL.The CD14+ CD16+ monocyte subset in rheumatoid arthritis and systemic lupus erythematosus.Rheumatol Int,2002,21:189-192.
[8]Martynova TV,Aleksiuk LI.Functional activity of the peritoneal macrophages in mice with concanavalin A-induced hepatitis.Fiziol Zh,2007,53:47-52.
[9]Tas SW,Quartier P,Botto M,et al.Macrophages from patients with SLEandrheumatoidarthritis have defective adhesion in vitro,while only SLE macrophages have impaired uptake of apoptotic cells.Ann Rheum Dis,2006,65:216-221.
[1O]Ren Y,Tang J,Mok MY,et al.Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus.Arthritis Rheum, 2003,48:2888-2897.
[11] Shoshan Y, Shapira I, Toubi E, et al. Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: relevance to in vitro impairment of interaction with iC3b-opsonized apoptotic cells. J Immunol, 2001, 167:5963-5969.
[12] Bijl M, Reefman E, Horst G, et al. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis,2006, 65:57-63.
[13] Grevink ME, Horst G, Limburg PC, et al.Levels of complement in sera from inactive SLE patients, although decreased, do not influence in vitro uptake of apoptotic cells. J Autoimmun, 2005,24:329-336.
[14] Allina J, Stanca CM, Garber J, et al.Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. J Autoimmun, 2007 17 [Epub ahead of print].
[15] Reefman E, Horst G, Nijk MT,et al. Opsonization of late apoptotic cells by systemic lupus erythematosus autoantibodies inhibits their uptake via an Fcgamma receptor-dependent mechanism. Arthritis Rheum,2007,56:3399-3411.
[16] O'Neill HC, Quah BJ. Exosomes secreted by bacterially infected macrophages are proinflammatory. Sci Signal, 2008, 1:pe8.
[17] Coutelier JP, Detalle L, Musaji A, et al. Two-step mechanism of virus-induced autoimmune hemolytic anemia. Ann N Y Acad Sci, 2007, 1109:151-157.
[18] Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.Am J Physiol Renal Physiol,2008 13 [Epub ahead of print].
[16]Sodhi A,Tripathi A.Prolactin and growth hormone induce differential cytokine and chemokine profile in murine peritoneal macrophages in vitro:involvement of p-38 MAP kinase,STAT3 and NF-kappaB.Cytokine,2008,41:162-173.
[20]Tripathi A,Sodhi A.Prolactin-induced production of cytokines in macrophages in vitro involves JAK/STAT and JNK MAPK pathways.Int Immunol,2008,20:327-336.
[21]Zhu B,Suzuki K,Goldberg HA,et al.Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors:evidence of a role for an intracellular form of osteopontin.J Cell Physiol,2004,198:155-167.
[22]Das R,Burke T,Plow EF Histone H2B as a functionally important plasminogen receptor on macrophages.Blood,2007,110:3763-3772.
[23]Sinha S,Kaler LJ,Proctor TM,et al.IL-13-Mediated Gender Difference in Susceptibility to Autoimmune Encephalomyelitis.J Immunol,2008,180:2679-2685.
[24]Wang H,Madariaga ML,Wang S,et al.Lack of CD47 on nonhematopoietic cells induces split macrophage tolerance to CD47null cells.Proc Natl Acad Sci U S A,2007,104:13744-13749.
[25]邢莉民，邵宗鸿，付蓉，等，自身免疫性血细胞减少症患者骨髓CD5+B细胞数量变化及其临床意义．中国实用内科杂志2005．25(11)：994-996．
[26]高晓明．医学免疫学基础．第一版．北京：北京大学医学出版社，2005．138-154．
[27]Toriani-Terenzi C,Fagiolo E.Th2 cytokine role in autoimmune haemolytic anaemia(AIHA)pathogenesis.Panminerva Ned.2001,43(1)
[28] Toriani-Terenzi C, Pozzetto U, Bianchi M, et al Cytokine network in autoimmune haemolytic anaemia: new probable targets for therapy. Cancer Detect Prev. 2002, 26(4):292-298.
[29] Fagiolo E, Toriani-Terenzi C. Th1 and Th2 cytokine modulation by IL—10/IL—12 imbalance in autoimmune haemolytic anaemia (AIHA).Autoimmunity. 2002,35(1):39-44.
[30] Ahn, Eckhard Podack, Wenche Jy. et al. Soluble CD30 (sCD30),a Marker of Th2 Polarization, Is Elevated in Patients with Autoimmune Hemolytic Anemia (AIHA) but Not with Idiopathic Thrombocytopenia (ITP).Eugene R. Blood (ASH Annual Meeting Abstracts),2005, 106:1248.
[31] Lim HW, Hillsamer P, Banham AH, et al. Cutting edge :direct suppression of B cells by CD4+CD25+ regulatory T cells. J Immunol,2005,175(7):4180-4183.
[32] Mqadmi A, Zheng X, Yazdanbakhsh K.CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. Blood.2005 ,105(9): 3746-3748.
[33] Okazaki T, Iwai Y,Honjo T.New regulatory co-receptors:inducible costimulator and PD-1.Curr Opin Immunol.2002, 14(6):779-782.
[34] Iwai Y, Terawaki S, Ikegawa M, et al.PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med,2003,198(1):39-50.
[35] Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol, 2001. 19:275-290.
[36] Pritchard NR, Smith KG. B cell inhibitory receptors and autoimmunity.immunology, 2003, 108(3):263-273.
[37]Davis RS,Ehrhardt GR,Leu MC,et al.An extended family of Fc receptor relatives.Eer J Immunol,2005,35(3):674-680.
[38]Chaim O.Jacob ,Luminita Pricop,Chaim Putterman,et al.Paucity of Clinical Disease despite Serological Autoimmunity and Kidney Pathology in Lupus-Prone New Zealand Mixed 2328 Mice Deficient in BAFF.The Journal of Immunology,2006,177:2671-2680.
[39]Straus SE,Sneller M,Lenardo MJ,et al.An inhereited disorder of lymphocyte apoptosis:the autoimmune lymphoproliferative syndrome.Ann intern Med,1999.130(7):591-601.
[40]Watanabe N,Ikuta K,Nisitani S,et al.Activation and differentiation of autoreactive B-1 cells by interleukin 10 induce autoimmune hemolytic anemia in Fas-deficient antierythrocyte immunoglobulin transgenic mice.J Exp Med.2002 ,196(1):141-146.
[41]Suzuki A,Sasaki T,Mak TW,et al.Functional analysis of the tumour suppressor gene PTEN in murine B cells and keratinocytes.Biochem Soc Trans,2004,(32Pt):362-365.
[42]Brown KS,Blair D,Reid SD,et al.FcgammaR Ⅱ b-mediated negative regulation of BCR signaling is associated with the recruitment of the MAPkinase-phosphatase,Pac-l,and the 3’ -inositol phosphatase,PTEN.Cell Signal,2004,16(1):71-80.
[43]张欣，高清平，王琼玉，等．B淋巴细胞的周期蛋白表达及周期分布在特发性血小板减少性紫癜发病机制中的意义．中华血液学杂志，2006．27(9)： 630-631．
[44]Hoffman PC.Immune hemolytic anemia--selected topics.Hematology Am Soc Hematol Educ Program.2006:3-8.
[45]Toriani-Terenzi C,Fagio]o E.Th2 cytokine role in autoimmune haemolytic anaemia(AIHA)pathogenesis.Panminerva Med.2001,3(1):1-5.
[46]Toriani-Terenzi C,Pozzetto U,Bianchi M,et al Cytokine network in autoimmune haemolytic anaemia:new probable targets for therapy.Cancer Detect Prev.2002,26(4):292-298.
[47]Mqadmi A,Zheng X,Yazdanbakhsh K.CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia.Blood.2005,5(9):3746-3748.
[48]付蓉，邵宗鸿，刘鸿，等．与免疫相关的全血细胞减少患者骨髓造血细胞自身抗体的研究．中华血液学杂志，2003，4(4)：177—180．
[49]邵宗鸿，付蓉．免疫相关性血细胞减少症—一种新认知的疾病(上)．中国医刊，2005．40(1)：5-8．
[50]邵宗鸿，付蓉．免疫相关性血细胞减少症—一种新认知的疾病(下)．中国医刊，2005．40(2)：6-9．
[51]付蓉，邵宗鸿，和虹，等．免疫相关性全血细胞减少症患者骨髓B淋巴细胞数量及凋亡相关蛋白水平．中华血液学杂志，2002．23(5)：236-238．
[52]侯明，秦平．特发性血小板减少性紫癜的基础与临床进展．第九次全国血液学年会学术会议，2006．1 0：55-59．
[53]McMillan R,Lopez-Dee J,Bowditch.Clonal restriction of platelet associated anti-GP autoantibodies in patients with chronic ITP.Thromb Haemost,2001,85:821-823.
[54]Roark JH,Bussel JB,Cines DB,et al.Genetic analysis of autoanti -bodies in idiopathic thrombocytopenic purura reveals evidence of clona]expansion and somatic mutation.Blood,2002,100:1388-1398.
[55]Mei Chang,Peggy A.Nakagawa,etal.Immune thrombocytopenic purpura(ITP)plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro Blood,2003,02:887-895.
[56]石艳，侯明，彭军，等．自身免疫性血小板减少性紫癜特异性自身抗体的克隆性分析．第九届全国实验血液学会议论文摘要汇编．2003．196-197．
[57]MihaFurlan,RodolfoRobles,MiriamGalbusera,etal.vonWillebrand Factor-Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic-Uremic Syndrome.N.Engl.J.Med,1998,39:1578-584.
[58]Han-Mou Tsai,Eric Chun-Yet Lian.Antibodies to von Willebrand Factor-Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura.N.Engl.J.Med,998,39:1585-594.
[59]Bux J,Behrens G,Jaeger G,etal.Diagnosis and clinical course ofautoimmuneneutropeniaininfancy:analysis of 240 cases.Blood,1998,91(1):181-186.
[60]袁燕，谢毅．全血法流式细胞术检测中性粒细胞抗体方法建立及临床应用．诊断理论与实践．2004．3(6)：409-411．